JP2010500404A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010500404A5 JP2010500404A5 JP2009524621A JP2009524621A JP2010500404A5 JP 2010500404 A5 JP2010500404 A5 JP 2010500404A5 JP 2009524621 A JP2009524621 A JP 2009524621A JP 2009524621 A JP2009524621 A JP 2009524621A JP 2010500404 A5 JP2010500404 A5 JP 2010500404A5
- Authority
- JP
- Japan
- Prior art keywords
- delivery system
- drug delivery
- prodrug
- derivative
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000012377 drug delivery Methods 0.000 claims 26
- 229940002612 prodrug Drugs 0.000 claims 17
- 239000000651 prodrug Substances 0.000 claims 17
- 150000003839 salts Chemical class 0.000 claims 16
- 229930012538 Paclitaxel Natural products 0.000 claims 10
- 229960001592 paclitaxel Drugs 0.000 claims 10
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 10
- CGTADGCBEXYWNE-JUKNQOCSSA-N zotarolimus Chemical compound N1([C@H]2CC[C@@H](C[C@@H](C)[C@H]3OC(=O)[C@@H]4CCCCN4C(=O)C(=O)[C@@]4(O)[C@H](C)CC[C@H](O4)C[C@@H](/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C3)OC)C[C@H]2OC)C=NN=N1 CGTADGCBEXYWNE-JUKNQOCSSA-N 0.000 claims 10
- 229950009819 zotarolimus Drugs 0.000 claims 10
- 239000000203 mixture Substances 0.000 claims 6
- 229960002930 sirolimus Drugs 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 5
- 206010020718 hyperplasia Diseases 0.000 claims 5
- 239000003146 anticoagulant agent Substances 0.000 claims 4
- -1 antifabric Substances 0.000 claims 3
- 239000011248 coating agent Substances 0.000 claims 3
- 238000000576 coating method Methods 0.000 claims 3
- 238000005259 measurement Methods 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 claims 2
- XUXUHDYTLNCYQQ-UHFFFAOYSA-N 4-amino-TEMPO Chemical group CC1(C)CC(N)CC(C)(C)N1[O] XUXUHDYTLNCYQQ-UHFFFAOYSA-N 0.000 claims 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 102000019197 Superoxide Dismutase Human genes 0.000 claims 2
- 108010012715 Superoxide dismutase Proteins 0.000 claims 2
- 208000007536 Thrombosis Diseases 0.000 claims 2
- 229960002842 clobetasol Drugs 0.000 claims 2
- CBGUOGMQLZIXBE-XGQKBEPLSA-N clobetasol propionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CCl)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CBGUOGMQLZIXBE-XGQKBEPLSA-N 0.000 claims 2
- 230000000295 complement effect Effects 0.000 claims 2
- 229960003957 dexamethasone Drugs 0.000 claims 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 229960005309 estradiol Drugs 0.000 claims 2
- 229930182833 estradiol Natural products 0.000 claims 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims 2
- 208000037803 restenosis Diseases 0.000 claims 2
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 206010002329 Aneurysm Diseases 0.000 claims 1
- 206010056375 Bile duct obstruction Diseases 0.000 claims 1
- 206010008635 Cholestasis Diseases 0.000 claims 1
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 claims 1
- 208000032843 Hemorrhage Diseases 0.000 claims 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 claims 1
- 208000008883 Patent Foramen Ovale Diseases 0.000 claims 1
- 208000031481 Pathologic Constriction Diseases 0.000 claims 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims 1
- 208000004608 Ureteral Obstruction Diseases 0.000 claims 1
- 206010070693 Vascular dissection Diseases 0.000 claims 1
- 229960002964 adalimumab Drugs 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 230000003872 anastomosis Effects 0.000 claims 1
- 230000003266 anti-allergic effect Effects 0.000 claims 1
- 230000000844 anti-bacterial effect Effects 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 230000003110 anti-inflammatory effect Effects 0.000 claims 1
- 230000002927 anti-mitotic effect Effects 0.000 claims 1
- 230000000702 anti-platelet effect Effects 0.000 claims 1
- 230000001028 anti-proliverative effect Effects 0.000 claims 1
- 230000002785 anti-thrombosis Effects 0.000 claims 1
- 230000000259 anti-tumor effect Effects 0.000 claims 1
- 229940127219 anticoagulant drug Drugs 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 230000003078 antioxidant effect Effects 0.000 claims 1
- 239000004019 antithrombin Substances 0.000 claims 1
- 210000003363 arteriovenous anastomosis Anatomy 0.000 claims 1
- 208000034158 bleeding Diseases 0.000 claims 1
- 230000000740 bleeding effect Effects 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 238000013270 controlled release Methods 0.000 claims 1
- 229960003668 docetaxel Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 1
- 229960005167 everolimus Drugs 0.000 claims 1
- 229960002714 fluticasone Drugs 0.000 claims 1
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 claims 1
- 229960000890 hydrocortisone Drugs 0.000 claims 1
- 229960001680 ibuprofen Drugs 0.000 claims 1
- 229960003685 imatinib mesylate Drugs 0.000 claims 1
- YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 208000030175 lameness Diseases 0.000 claims 1
- 238000000691 measurement method Methods 0.000 claims 1
- 229960001664 mometasone Drugs 0.000 claims 1
- QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 claims 1
- 229960002009 naproxen Drugs 0.000 claims 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims 1
- 239000002840 nitric oxide donor Substances 0.000 claims 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 1
- 229960005489 paracetamol Drugs 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- KASDHRXLYQOAKZ-ZPSXYTITSA-N pimecrolimus Chemical compound C/C([C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@@H](OC)C[C@@H](C)C/C(C)=C/[C@H](C(C[C@H](O)[C@H]1C)=O)CC)=C\[C@@H]1CC[C@@H](Cl)[C@H](OC)C1 KASDHRXLYQOAKZ-ZPSXYTITSA-N 0.000 claims 1
- 229960005330 pimecrolimus Drugs 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
- 208000037804 stenosis Diseases 0.000 claims 1
- 230000036262 stenosis Effects 0.000 claims 1
- 230000003637 steroidlike Effects 0.000 claims 1
- 229960000894 sulindac Drugs 0.000 claims 1
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 claims 1
- 229960001967 tacrolimus Drugs 0.000 claims 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 230000002537 thrombolytic effect Effects 0.000 claims 1
- 229960005294 triamcinolone Drugs 0.000 claims 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 claims 1
- YYSFXUWWPNHNAZ-PKJQJFMNSA-N umirolimus Chemical compound C1[C@@H](OC)[C@H](OCCOCC)CC[C@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 YYSFXUWWPNHNAZ-PKJQJFMNSA-N 0.000 claims 1
- 208000026517 ureter neoplasm Diseases 0.000 claims 1
- 201000011476 ureteral benign neoplasm Diseases 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
- 210000003462 vein Anatomy 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/464,676 US7357942B2 (en) | 1997-09-26 | 2006-08-15 | Compositions, systems, and kits for administering zotarolimus and paclitaxel to blood vessel lumens |
| US11/464,667 US8257726B2 (en) | 1997-09-26 | 2006-08-15 | Compositions, systems, kits, and methods of administering rapamycin analogs with paclitaxel using medical devices |
| US11/464,659 | 2006-08-15 | ||
| US11/464,659 US7378105B2 (en) | 1997-09-26 | 2006-08-15 | Drug delivery systems, kits, and methods for administering zotarolimus and paclitaxel to blood vessel lumens |
| US11/464,676 | 2006-08-15 | ||
| US11/464,667 | 2006-08-15 | ||
| PCT/US2007/017619 WO2008021124A2 (en) | 2006-08-15 | 2007-08-07 | Compositions and drug-delivery systems comprising rapamycin analogs and paclitaxel |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010500404A JP2010500404A (ja) | 2010-01-07 |
| JP2010500404A5 true JP2010500404A5 (enExample) | 2010-09-24 |
| JP5541593B2 JP5541593B2 (ja) | 2014-07-09 |
Family
ID=38941900
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009524621A Active JP5541593B2 (ja) | 2006-08-15 | 2007-08-07 | ラパマイシン類似体及びパクリタキセルを含む組成物及び薬物送達システム |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP2068932B1 (enExample) |
| JP (1) | JP5541593B2 (enExample) |
| WO (1) | WO2008021124A2 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8257726B2 (en) | 1997-09-26 | 2012-09-04 | Abbott Laboratories | Compositions, systems, kits, and methods of administering rapamycin analogs with paclitaxel using medical devices |
| US8394398B2 (en) | 1997-09-26 | 2013-03-12 | Abbott Laboratories | Methods of administering rapamycin analogs with anti-inflammatories using medical devices |
| US8057816B2 (en) * | 1997-09-26 | 2011-11-15 | Abbott Laboratories | Compositions and methods of administering paclitaxel with other drugs using medical devices |
| US8431145B2 (en) | 2004-03-19 | 2013-04-30 | Abbott Laboratories | Multiple drug delivery from a balloon and a prosthesis |
| US20100055145A1 (en) * | 2008-08-29 | 2010-03-04 | Biosensors International Group | Stent coatings for reducing late stent thrombosis |
| US8951595B2 (en) | 2009-12-11 | 2015-02-10 | Abbott Cardiovascular Systems Inc. | Coatings with tunable molecular architecture for drug-coated balloon |
| EP2380605A1 (en) * | 2010-04-19 | 2011-10-26 | InnoRa Gmbh | Improved formulations for drug-coated medical devices |
| EP2948134B1 (en) | 2013-01-24 | 2020-03-04 | Palvella Therapeutics, Inc. | Compositions for transdermal delivery of mtor inhibitors |
| IL267869B2 (en) | 2017-01-06 | 2023-10-01 | Palvella Therapeutics Inc | Non-aqueous preparations of mTOR inhibitors and methods of use |
| JP2021530463A (ja) | 2018-07-02 | 2021-11-11 | パルヴェラ セラピューティクス、インク． | ｍＴＯＲ阻害剤の無水組成物および使用方法 |
| DE102019116791B4 (de) * | 2019-06-21 | 2023-10-26 | InnoRa Gesellschaft mbH | Stent mit sofort ablösbarer Beschichtung |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7399480B2 (en) * | 1997-09-26 | 2008-07-15 | Abbott Laboratories | Methods of administering tetrazole-containing rapamycin analogs with other therapeutic substances using medical devices |
| US7419678B2 (en) * | 2000-05-12 | 2008-09-02 | Cordis Corporation | Coated medical devices for the prevention and treatment of vascular disease |
| US20050004158A1 (en) * | 2003-06-19 | 2005-01-06 | Vascular Therapies Llc | Medical implants and methods for regulating the tissue response to vascular closure devices |
| US20050019404A1 (en) * | 2003-06-30 | 2005-01-27 | Hsing-Wen Sung | Drug-eluting biodegradable stent |
| EP2301619B1 (en) * | 2004-03-19 | 2017-05-10 | Abbott Laboratories | Multiple drug delivery from a balloon and a prosthesis |
| US7820732B2 (en) * | 2004-04-30 | 2010-10-26 | Advanced Cardiovascular Systems, Inc. | Methods for modulating thermal and mechanical properties of coatings on implantable devices |
| US20050288481A1 (en) * | 2004-04-30 | 2005-12-29 | Desnoyer Jessica R | Design of poly(ester amides) for the control of agent-release from polymeric compositions |
| WO2007032777A2 (en) * | 2005-03-23 | 2007-03-22 | Abbott Laboratories | Compositions and methods of administering rapamycin analogs using medical devices for long-term efficacy |
| WO2007046935A2 (en) * | 2005-10-14 | 2007-04-26 | Abbott Laboratories | Compositions, systems, kits, and methods of administering rapamycin analogs with paclitaxel using medical devices |
-
2007
- 2007-08-07 EP EP07836616.8A patent/EP2068932B1/en active Active
- 2007-08-07 WO PCT/US2007/017619 patent/WO2008021124A2/en not_active Ceased
- 2007-08-07 JP JP2009524621A patent/JP5541593B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010500404A5 (enExample) | ||
| JP5594534B2 (ja) | 調節可能な疎水性を備えた生体吸収性コーティング | |
| US8586069B2 (en) | Anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders | |
| EP2327429B1 (en) | Delivery of highly lipophilic agents via medical devices | |
| JP5791221B2 (ja) | 血管疾患の治療のための抗増殖薬と抗炎症薬の組み合わせ | |
| JP5366155B2 (ja) | 血栓症を低減するためにホスホリルコリンアクリレートポリマーの上塗層を備え、機械特性が改善された埋め込み型医療デバイス | |
| ES2479193T3 (es) | Revestimientos incluyendo acetato de dexametasona y fármacos olimus | |
| US8048441B2 (en) | Nanobead releasing medical devices | |
| US8435550B2 (en) | Anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders with an implantable medical device | |
| CN103561791B (zh) | 涂覆有紫杉醇组合物的可扩张装置 | |
| ES2445097T3 (es) | Dispositivos médicos implantables y revestimientos para los mismos comprendiendo copolímeros bloque y copolímeros de polietilenglicol y un poli(láctido-glicoido) | |
| US20100030183A1 (en) | Method of treating vascular disease at a bifurcated vessel using a coated balloon | |
| JP5982688B2 (ja) | 埋込み型デバイス用の吸収性コーティング | |
| Miyauchi et al. | Effectiveness of statin-eluting stent on early inflammatory response and neointimal thickness in a porcine coronary model | |
| EP1996247A2 (en) | Nitric oxide generating medical devices | |
| JP6387359B2 (ja) | ラパマイシン誘導体を含む埋め込み型医療用デバイスの製造方法 | |
| JP6103606B2 (ja) | カプロラクトン及びグリコリドを含むターポリマーを含むコーティング | |
| JP2014221398A (ja) | 非晶質下塗り層及び半結晶性貯蔵層を含むコーティング | |
| US9220759B2 (en) | Treatment of diabetic patients with a drug eluting stent and adjunctive therapy | |
| JP2015186587A (ja) | 非晶質ターポリマー及び半結晶性ブロックを含むポリマー | |
| JP5542052B2 (ja) | 薄い吸収性コーティングを有する埋め込み型医療器具 | |
| CN105025946B (zh) | 包含大环三烯内酯药物和最少抗氧化稳定剂的可植入医疗装置及制造方法 | |
| JP2008534074A5 (enExample) | ||
| JP2015520147A (ja) | 血管病変を治療する改善された方法 |